Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
AstraZeneca
Harvard Business School
Boehringer Ingelheim
Teva
Chinese Patent Office
US Department of Justice
Cerilliant
Covington
Medtronic

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,476,052

« Back to Dashboard

Which drugs does patent 6,476,052 protect, and when does it expire?


Patent 6,476,052 protects POMALYST and is included in one NDA. There has been one Paragraph IV challenge on Pomalyst.

This patent has one hundred and nine patent family members in twenty-six countries.

Summary for Patent: 6,476,052

Title: Isoindolines, method of use, and pharmaceutical compositions
Abstract:Substituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are useful in treating inflammation, inflammatory disease, autoimmune disease, and oncogenic or cancerous conditions in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxopiperidin-3yl)4-aminoisoindoline and 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)aminoisoindoline.
Inventor(s): Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ)
Assignee: Celgene Corporation (Warren, NJ)
Application Number:09/633,908
Patent Claim Types:
see list of patent claims
Use; Compound; Delivery; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-001Feb 8, 2013RXYesNo► Subscribe► SubscribeY USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-002Feb 8, 2013RXYesNo► Subscribe► SubscribeY USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-003Feb 8, 2013RXYesNo► Subscribe► SubscribeY USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-004Feb 8, 2013RXYesYes► Subscribe► SubscribeY USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,476,052

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,316,471 Isoindolines, method of use, and pharmaceutical compositions► Subscribe
8,288,415Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione► Subscribe
7,709,502Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines► Subscribe
5,635,517 Method of reducing TNF.alpha. levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines► Subscribe
6,555,554 Isoindolines, method of use, and pharmaceutical compositions► Subscribe
8,158,653Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline► Subscribe
7,041,680(R) and (S) isomers of substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxoisoindolines and methods of using the same► Subscribe
5,798,368 Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNF.alpha. levels► Subscribe
7,629,360Methods for the treatment of cachexia and graft v. host disease► Subscribe
6,281,230 Isoindolines, method of use, and pharmaceutical compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,476,052

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea20010013097► Subscribe
Japan2015131863► Subscribe
South Korea100526212► Subscribe
South Korea20000068008► Subscribe
Hong Kong1153736► Subscribe
Hong Kong1132502► Subscribe
Finland992490► Subscribe
Hong Kong1021819► Subscribe
Hong Kong1050893► Subscribe
Spain2529190► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cantor Fitzgerald
Moodys
Federal Trade Commission
Accenture
Julphar
Teva
US Army
Baxter
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot